Ameliorative effects of pirfenidone in chronic kidney disease

Ameliorative effects of pirfenidone in chronic kidney disease

Renal fibrosis is the hallmark of advanced chronic kidney disease (CKD), which is characterized by excessive accumulation of extracellular matrix (ECM) proteins and plays a central role in the pathogenesis and progression of CKD to end-stage renal disease (ESRD). The molecular and cellular substance...

Full description

Bibliographic Details
Main Authors:	Samad Ghodrati, Yeganeh Ragati Haghi, Jyoti Baharani, Akshaya Joseph, Niloufar Alimohammadi, Farzad Koosha, Leila Mostafavi, Aiyoub Pezeshgi
Format:	Article
Language:	English
Published:	Society of Diabetic Nephropathy Prevention 2022-07-01
Series:	Journal of Nephropharmacology
Subjects:	pirfenidone chronic kidney disease transforming growth factor beta end-stage renal disease
Online Access:	https://jnephropharmacology.com/PDF/npj-11-e10458.pdf

Similar Items

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone use in fibrotic diseases: What do we know so far?
by: Aldo Torre, et al.
Published: (2024-07-01)

Effect of allopurinol on the treatment of chronic kidney disease: a systematic review and meta-analysis
by: Aiyoub Pezeshgi, et al.
Published: (2023-01-01)

Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
by: Ho Young Lee, et al.
Published: (2023-10-01)

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
by: Zarir F Udwadia, et al.
Published: (2015-01-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
by: Mark H. Gotfried, et al.
Published: (2018-06-01)

Effect of pirfenidone on tendon healing
by: Yasemin Aydinli, et al.
Published: (2023-01-01)

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024-05-01)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
by: Jiang Z, et al.
Published: (2022-12-01)

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
by: Giulia Cassone, et al.
Published: (2020-01-01)

Preparation of Novel Pirfenidone Microspheres for Lung-Targeted Delivery: In vitro and in vivo Study [Retraction]
by: Li D, et al.
Published: (2022-11-01)

Inhibition of urethral stricture by a catheter loaded with nanoparticle/ pirfenidone complexes
by: Wei Meng, et al.
Published: (2023-10-01)

Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice
by: Nana Liu, et al.
Published: (2024-01-01)

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
by: Julie Stougaard, et al.
Published: (2018-11-01)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
by: Carlos Daniel Diaz-Palomera, et al.
Published: (2022-01-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Combination of Niclosamide and Pirfenidone Alleviates Pulmonary Fibrosis by Inhibiting Oxidative Stress and MAPK/Nf-κB and STATs Regulated Genes
by: Hanaa Wanas, et al.
Published: (2023-05-01)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
by: Paolo Cameli, et al.
Published: (2020-09-01)

Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series
by: Brandon Iturbe Esquivel, et al.
Published: (2022-06-01)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2018-01-01)

Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts
by: Yingying Cui, et al.
Published: (2020-03-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review
by: Mingfeng Han, et al.
Published: (2024-08-01)

Pirfenidone combined with N-acetylcysteine in treatment of pulmonary fibrosis: a case report and literature review
by: Li Wenjuan, Zhang Liyi, Zhou Yuqi
Published: (2022-01-01)

Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models
by: Laura Sartiani, et al.
Published: (2022-09-01)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
by: Jelle R. Miedema, et al.
Published: (2022-05-01)

Effectiveness of upfront triple oral combination therapy with additional pirfenidone in a patient with severe pulmonary hypertension associated with lung diseases
by: Fumihiro Kashizaki, et al.
Published: (2024-08-01)

Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
by: Xianglin Zhou, et al.
Published: (2022-06-01)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
by: Hui Li, et al.
Published: (2022-11-01)

COVID-19 lung lesion treated with pirfenidone and effective rehabilitation: A Case Report
by: L. Zaldívar Vázquez, et al.
Published: (2022-09-01)

Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways
by: Qiong Tang, et al.
Published: (2022-10-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

Cholesterol Significantly Affects the Interactions between Pirfenidone and DPPC Liposomes: Spectroscopic Studies
by: Irina M. Le-Deygen, et al.
Published: (2022-02-01)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024-06-01)

Intra-articular sustained-release of pirfenidone as a disease-modifying treatment for early osteoarthritis
by: Xiaobo Zhu, et al.
Published: (2024-09-01)

A Soft Skin Adhesive (SSA) Patch for Extended Release of Pirfenidone in Burn Wounds
by: Eugene P. Chung, et al.
Published: (2023-06-01)

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
by: Yasuhiko Koga, et al.
Published: (2019-05-01)

Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis
by: Kiran Dudhat, et al.
Published: (2022-06-01)